Programmed cell death protein-1- checkpoint blockers have recently been approved as second-line treatment for advanced non–small-cell lung cancer (NSCLC). Unfortunately, only a subgroup of patients responds and shows long-term survival to these therapies. Tumor vaccines and cellular immunotherapies could synergize with checkpoint blockade, but which of these treatments is most efficacious is unknown. In this meta-analysis, we assessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC. We searched for randomized controlled trials (RCTs) investigating … (leggi tutto)
In un contesto dove tantissimi studi sono ongoing, molti risultati stanno emergendo e tantissimi quesiti restano ancora in sospeso … poteva essere utile avere un dato metanalitico. In realtà, purtroppo, questa metanalisi non ci fornisce grosse risposte, ma è comunque un riassunto dei principali trials, in modo trasversale, con diverse molecole, differenti setting e istologie.
